Skip to main content
Advertisement
Advertisement

ENGN

ENGN logo

enGene Therapeutics Inc. Common Stock

1.91
USD
Sponsored
0.00
0.00%
Sep 18, 15:57 UTC -4
Closed
exchange

After-Market

1.91

0.00
-0.21%

ENGN Earnings Reports

Positive Surprise Ratio

ENGN beat 4 of 10 last estimates.

40%

Next Report

Date of Next Report
Dec 22, 2026
Estimate for Q4 26 (Revenue/ EPS)
--
/
-$0.44
Implied change from Q3 26 (Revenue/ EPS)
--
/
-6.38%
Implied change from Q4 25 (Revenue/ EPS)
--
/
-39.73%

enGene Therapeutics Inc. Common Stock earnings per share and revenue

On Sep 08, 2026, ENGN reported earnings of -0.47 USD per share (EPS) for Q3 26, missing the estimate of -0.43 USD, resulting in a -7.16% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +5.49% price change (close before vs. close after earnings).
Looking ahead to Q4 26, 11 analysts forecast an EPS of -0.44 USD, with revenue projected to reach -- USD, implying an decrease of -6.38% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Anixa Biosciences, Inc.
Report Date
Sep 09, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+8.78%
logo
Alzamend Neuro, Inc. Common Stock
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.57
Actual
-$0.68
Surprise
-19.05%
FAQ
For Q3 2026, enGene Therapeutics Inc. Common Stock reported EPS of -$0.47, missing estimates by -7.16%, and revenue of $0.00, 0% as expectations.
The stock price moved up 5.49%, changed from $1.82 before the earnings release to $1.92 the day after.
The next earning report is scheduled for Dec 22, 2026.
Based on 11 analysts, enGene Therapeutics Inc. Common Stock is expected to report EPS of -$0.44 and revenue of -- for Q4 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement